Stock listing
Bridgebio Oncology Therapeutics, Inc.
Selected listing: BBOT · NASDAQ · USD · US
Bridgebio Oncology Therapeutics, Inc. (NASDAQ:BBOT), Health Technology. Latest release Sep 8, 2026: BBOT Announces New BBO-8520 Data; Highlights Strategic…
- Ticker
- NASDAQ:BBOT
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
About Bridgebio Oncology Therapeutics, Inc.
Bridgebio Oncology Therapeutics, Inc. is a public company listed under the ticker BBOT, operating in the American market. The company focuses on developing innovative therapies for cancer treatment.
Latest news from Bridgebio Oncology Therapeutics, Inc.
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
September 8, 2026
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
August 11, 2026
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
May 12, 2026
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
April 22, 2026
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
April 21, 2026
Research Bridgebio Oncology Therapeutics, Inc.
Bridgebio Oncology Therapeutics, Inc. company profile
View the public company page for Bridgebio Oncology Therapeutics, Inc. on 6ix.
Bridgebio Oncology Therapeutics, Inc. news
Read company news and market updates connected to Bridgebio Oncology Therapeutics, Inc..
Bridgebio Oncology Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Bridgebio Oncology Therapeutics, Inc..